ConductScience.org, home

Paper33972740

RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor.

Chen Y and 6 others. Cell Mol Immunol, 2021. Cited by 124 papers, by iCite.

Cite this record

ConductScience Library. RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Papers, record 33972740. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33972740

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor.
PubMed
Journal
Cell Mol Immunol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
124
iCite
Relative citation ratio, by iCite
7.38
iCite
Revised in PubMed
2024-02-26
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen YYun
2He HHongbin
3Lin BBolong
4Chen YYun
5Deng XXianming
6Jiang WWei
7Zhou RRongbinhttps://orcid.org/0000-0002-3351-6420

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AzetidinesMajor topic
InflammationMajor topic
NLR Family, Pyrin Domain-Containing 3 ProteinMajor topic
Nitro CompoundsMajor topic
Animals
CARD Signaling Adaptor Proteins
Colitis
Cysteine
Dextran Sulfate
Encephalomyelitis, Autoimmune, Experimental
Inflammasomes
Lipopolysaccharides
Macrophages
Mice, Inbred C57BL
NIMA-Related Kinases
Protein Domains
Mice

Source PubMed

Download CSV of topics

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119302040The inflammasomes: guardians of the body.Annu Rev Immunol2009https://conductscience.org/library/papers/19302040PubMed
221219188The inflammasome NLRs in immunity, inflammation, and associated diseases.Annu Rev Immunol2011https://conductscience.org/library/papers/21219188PubMed
327291964Inflammasomes: mechanism of assembly, regulation and signalling.Nat Rev Immunol2016https://conductscience.org/library/papers/27291964PubMed
416407889Gout-associated uric acid crystals activate the NALP3 inflammasome.Nature2006https://conductscience.org/library/papers/16407889PubMed
520835230Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes.Nat Immunol2010https://conductscience.org/library/papers/20835230PubMed
621478880Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling.Nat Immunol2011https://conductscience.org/library/papers/21478880PubMed
723254930NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.Nature2013https://conductscience.org/library/papers/23254930PubMed
820428172NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.Nature2010https://conductscience.org/library/papers/20428172PubMed
920442201Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome.Gut2010https://conductscience.org/library/papers/20442201PubMed
1020303296The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis.Immunity2010https://conductscience.org/library/papers/20303296PubMed
1122974247Inflammasomes and their roles in health and disease.Annu Rev Cell Dev Biol2012https://conductscience.org/library/papers/22974247PubMed
12242653163,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome.J Biol Chem2014https://conductscience.org/library/papers/24265316PubMed
1325686105A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.Nat Med2015https://conductscience.org/library/papers/25686105PubMed
1429021150Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.J Exp Med2017https://conductscience.org/library/papers/29021150PubMed
1529959312Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.Nat Commun2018https://conductscience.org/library/papers/29959312PubMed
1629378952OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.Proc Natl Acad Sci U S A2018https://conductscience.org/library/papers/29378952PubMed
1731086327MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition.Nat Chem Biol2019https://conductscience.org/library/papers/31086327PubMed
1833005902Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.Lancet Rheumatol2020https://conductscience.org/library/papers/33005902PubMed
1927084426Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.Transl Oncol2016https://conductscience.org/library/papers/27084426PubMed
2031231122RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.Br J Cancer2019https://conductscience.org/library/papers/31231122PubMed

See all 48 referencesDownload CSV of references

Cited by76

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 124 citations.

PMIDTitleJournalYearIn PapersSource
42272621Progress in the Treatment of Ulcerative Colitis by Targeting NLRP3 Inflammasome.Drug Des Devel Ther2026https://conductscience.org/library/papers/42272621PubMed
42154002Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42154002PubMed
42039709High-Throughput Screening Reveals That CeeNU Acts as a New NLRP3 Inflammasome Inhibitor.MedComm (2020)2026https://conductscience.org/library/papers/42039709PubMed
41843135ML364 ameliorates NLRP3-induced inflammatory response.Inflamm Res2026https://conductscience.org/library/papers/41843135PubMed
41231359ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity.Mol Biomed2025https://conductscience.org/library/papers/41231359PubMed
40642495Immune cell metabolism in cancer drug resistance: Advances in target discovery and clinical translation.Chin J Cancer Res2025https://conductscience.org/library/papers/40642495PubMed
40492417Pinosylvin Inhibits Inflammatory and Osteoclastogenesis via NLRP3 Inflammasome.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40492417PubMed
40425567Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly.Nat Commun2025https://conductscience.org/library/papers/40425567PubMed
40374417Targeting the NLRP3 inflammasome for inflammatory disease therapy.Trends Pharmacol Sci2025https://conductscience.org/library/papers/40374417PubMed
40372511Targeting cholesterol-driven pyroptosis: a promising strategy for the prevention and treatment of atherosclerosis.Mol Biol Rep2025https://conductscience.org/library/papers/40372511PubMed
40370770Pharmacologic Targeting of PDIA1 Inhibits NLRP3 Inflammasome Assembly and Activation.Isr J Chem2024https://conductscience.org/library/papers/40370770PubMed
40326096NLRP3 Inflammasome in Vascular Dementia: Regulatory Mechanisms, Functions, and Therapeutic Implications: A Comprehensive Review.CNS Neurosci Ther2025https://conductscience.org/library/papers/40326096PubMed
40307577Updated insights into the molecular networks for NLRP3 inflammasome activation.Cell Mol Immunol2025https://conductscience.org/library/papers/40307577PubMed
40185713A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity.Cell Death Dis2025https://conductscience.org/library/papers/40185713PubMed
40100493New Insights on the Potential Role of Pyroptosis in Parkinson's Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics.Mol Neurobiol2025https://conductscience.org/library/papers/40100493PubMed
39979245Lactylation in cancer: metabolic mechanism and therapeutic strategies.Cell Death Discov2025https://conductscience.org/library/papers/39979245PubMed
39934538A review on NLRP3 inflammasome modulation by animal venom proteins/peptides: mechanisms and therapeutic insights.Inflammopharmacology2025https://conductscience.org/library/papers/39934538PubMed
39929578Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors.Adv Pharmacol2025https://conductscience.org/library/papers/39929578PubMed
39875780Research Progress in the Molecular Mechanism of NLRP3 Inflammasome in Alzheimer's Disease and Regulation by Natural Plant Products.Mol Neurobiol2025https://conductscience.org/library/papers/39875780PubMed
39690733Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology.CNS Neurosci Ther2024https://conductscience.org/library/papers/39690733PubMed

See all 76 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33972740

GET https://conductscience.org/api/papers/v1/33972740/references?page=2